Bernard Ravina Sells 5,490 Shares of Voyager Therapeutics, Inc. (VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) insider Bernard Ravina sold 5,490 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $13.26, for a total transaction of $72,797.40. Following the sale, the insider now directly owns 16,473 shares in the company, valued at $218,431.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Bernard Ravina also recently made the following trade(s):

  • On Tuesday, October 10th, Bernard Ravina sold 10,980 shares of Voyager Therapeutics stock. The shares were sold at an average price of $20.33, for a total transaction of $223,223.40.
  • On Monday, September 11th, Bernard Ravina sold 16,470 shares of Voyager Therapeutics stock. The shares were sold at an average price of $12.87, for a total transaction of $211,968.90.
  • On Tuesday, September 5th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The shares were sold at an average price of $10.00, for a total transaction of $54,900.00.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) opened at $12.35 on Wednesday. Voyager Therapeutics, Inc. has a twelve month low of $8.10 and a twelve month high of $25.99.

ILLEGAL ACTIVITY WARNING: “Bernard Ravina Sells 5,490 Shares of Voyager Therapeutics, Inc. (VYGR) Stock” was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/11/15/bernard-ravina-sells-5490-shares-of-voyager-therapeutics-inc-vygr-stock.html.

VYGR has been the topic of several research analyst reports. Chardan Capital reissued a “hold” rating and set a $17.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Canaccord Genuity initiated coverage on shares of Voyager Therapeutics in a research note on Friday, October 27th. They set a “buy” rating and a $35.00 price target on the stock. ValuEngine raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. Stifel Nicolaus initiated coverage on shares of Voyager Therapeutics in a research note on Friday, July 28th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Raymond James Financial, Inc. initiated coverage on shares of Voyager Therapeutics in a research note on Thursday, October 12th. They set an “outperform” rating and a $35.00 price target on the stock. Three research analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. Voyager Therapeutics has a consensus rating of “Hold” and a consensus target price of $27.88.

A number of hedge funds and other institutional investors have recently made changes to their positions in VYGR. Russell Investments Group Ltd. lifted its holdings in Voyager Therapeutics by 57.7% in the second quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock valued at $106,000 after buying an additional 4,343 shares during the period. Hershey Trust Co. lifted its holdings in Voyager Therapeutics by 163.0% in the second quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock valued at $129,000 after buying an additional 8,921 shares during the period. Oppenheimer & Co. Inc. acquired a new stake in Voyager Therapeutics in the second quarter worth $143,000. Rhumbline Advisers raised its holdings in Voyager Therapeutics by 34.7% in the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock worth $144,000 after purchasing an additional 4,144 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in Voyager Therapeutics by 8.9% in the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after purchasing an additional 1,399 shares during the period. Institutional investors and hedge funds own 40.93% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply